Kolon Kanseri Hastalarında FOLFOX ve CAPOX’un CEA ve CA 19-9 Üzerine Etkisinin Araştırılması

Abstract

The most common markers used in the diagnosis of the colon cancer are CEA and CA 19-9. Chemotherapy is applied as an adjuvant and a neo-adjuvant treatment in colon cancer. Our aim was to investigate the effects of FOLFOX and CAPOX on CEA and CA 19-9 levels before and after chemotherapy in different patient groups. The CEA and CA 19-9 values before and after chemotherapy for the 60 patients diagnosed with metastatic colon cancer having FOLFOX or CAPOX therapy age over 18 whom hospitalised between 2017-2020, were used. The mean value for CA 19-9 of T0 for FOLFOX receiving group was calculated as 263.71 ± 709.87 U/ml and was 119.57 ± 246.34 U/ml of for the 3rd month. The mean value for CEA for receiving FOLFOX was calculated as 76.11 ± 204.22 ng/g at T0, and 50.53 ± 142.50 ng/g at the 3rd month. The mean value of CEA for receiving CAPOX was calculated as 139.62 ± 388.87 ng/g at T0, and 117.05 ± 272.08 ng/g at the 3rd month. Intertemporal CEA levels of individuals receiving CAPOX were found to show significant differences (p=0.074). CA 19-9 mean of T0 was calculated as 218.43 ± 605.53 U/ml and the 3rd month mean of 174.40 ± 465.61 U/ml of the patients receiving CAPOX. It was found that the intertemporal values of the individuals in terms of CA 19-9 levels were not statistically significant (p=0.649). In conclusion, CA 19-9 and CEA levels of the patients decreased even more in the 3rd month when treated with FOLFOX. The decrease in CEA was found to be more significant. In terms of CAPOX treatment, the interquartile range T0 and the 3rd month levels did not show a significant difference, statistically (p=0.143 and p=0.089).